Loading…
Protalix BioTherapeutics, Inc. is projected to rise to $3.12 by 2027, a +47% move from its current price of $2.12. PLX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.07 | $2.12 | $2.17 | +0.10% |
| May 30 | $2.05 | $2.12 | $2.20 | +0.20% |
| May 31 | $2.04 | $2.13 | $2.22 | +0.30% |
| Jun 1 | $2.03 | $2.13 | $2.23 | +0.40% |
| Jun 2 | $2.02 | $2.13 | $2.25 | +0.50% |
| Jun 3 | $2.01 | $2.13 | $2.26 | +0.60% |
| Jun 4 | $2.00 | $2.13 | $2.27 | +0.70% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.00 | $2.13 | $2.27 | +0.70% |
| Week 2 | $1.97 | $2.15 | $2.35 | +1.41% |
| Week 3 | $1.94 | $2.17 | $2.41 | +2.13% |
| Week 4 | $1.92 | $2.18 | $2.47 | +2.85% |
| Week 5 | $1.91 | $2.20 | $2.53 | +3.57% |
| Week 6 | $1.89 | $2.21 | $2.58 | +4.30% |
| Week 7 | $1.88 | $2.23 | $2.63 | +5.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company markets Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. Protalix has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc.
has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Protalix BioTherapeutics, Inc. (PLX) is a healthcare stock with a current price of $2.10 and a market cap of $169.2M. It ranks 3949 in market capitalization. The 2026 forecast shows a min of $1.74, an average of $2.10, and a max of $3.08, with an ROI of 0% and sentiment NEUTRAL.
From 2027 onward, the forecast envisions bullish momentum, with rising averages and higher ROIs through 2050, including 2030 avg $4.66, 2040 avg $17.20, and 2050 avg $37.72, with corresponding max prices and strong ROIs as indicated in the forecast.
A major floor 22.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 12.3% above — a clean break opens room to run.
A major ceiling 48.6% above — clearing it would confirm fresh momentum.
Key PLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.08 | Buy | $2.08 | Buy |
| MA 10 | $2.01 | Buy | $2.05 | Buy |
| MA 20 | $2.02 | Buy | $2.05 | Buy |
| MA 50 | $2.14 | Sell | $2.16 | Sell |
| MA 100 | $2.34 | Sell | $2.21 | Sell |
| MA 200 | $2.14 | Sell | $2.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.39 | Neutral |
| Stoch RSI (14) | 92.88 | Sell |
| CCI (20) | 88.80 | Neutral |
| Williams %R (14) | -8.33 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 9.28 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 91.67 | Sell |
| TRIX (15) | -0.47 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 63.21 | Neutral |
| Momentum (10) | 0.21 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 2.15 | Sell |
| ADX (14) | 19.97 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is bullish. RSI14 is 50, with the SMA50 at $2.17 and the SMA200 at $2.13. The stock shows a defined support at $1.90 and a resistance at $2.38, and the 30-day trading range spans from $1.78 to $2.48. Annualized volatility is 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.74 | $2.12 | $3.09 | 0% | Neutral | |
| $2.51 | $3.12 | $4.10 | +47% | Bullish | |
| $2.84 | $3.62 | $4.90 | +71% | Bullish | |
| $3.10 | $4.02 | $5.59 | +90% | Bullish | |
| $3.47 | $4.59 | $6.51 | +116% | Bullish | |
| $4.02 | $5.40 | $7.82 | +155% | Bullish | |
| $5.14 | $7.01 | $10.31 | +230% | Bullish | |
| $5.82 | $8.04 | $12.02 | +279% | Bullish | |
| $6.08 | $8.51 | $12.90 | +302% | Bullish | |
| $6.44 | $9.13 | $14.02 | +330% | Bullish | |
| $11.04 | $16.55 | $26.87 | +681% | Bullish | |
| $21.83 | $35.98 | $63.40 | +16.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.74 | $2.12 | $2.49 | +0.00% |
| June 2026 | $1.88 | $2.20 | $2.64 | +3.91% |
| July 2026 | $1.97 | $2.32 | $2.81 | +5.45% |
| August 2026 | $1.98 | $2.35 | $2.88 | +1.35% |
| September 2026 | $1.99 | $2.37 | $2.91 | +0.56% |
| October 2026 | $2.05 | $2.45 | $3.04 | +3.61% |
| November 2026 | $2.08 | $2.50 | $3.12 | +1.86% |
| December 2026 | $2.04 | $2.46 | $3.09 | -1.45% |
Click any year to see its month-by-month PLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PLX price prediction for 2026 points to an average of $2.12 (low $1.74, high $3.09) — a potential gain of 0% on today's $2.12. A consolidation phase looks the most probable path here.
In 2027, PLX is projected to trade between $2.51 and $4.10, averaging $3.12 — a potential gain of +47% from today's $2.12. That is up +47% on the projected 2026 average. Momentum favours further upside here.
Protalix BioTherapeutics, Inc.'s 2028 outlook centres on $3.62, within a $2.84 to $4.90 range. That is up +16% on the projected 2027 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PLX could reach as high as $5.59, with a base case around $4.02 and support toward $3.10 — roughly +90% from $2.12. Momentum favours further upside here.
Expect PLX to range from $3.47 to $6.51 through 2030. The $4.59 average target implies a +116% move from current prices. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PLX price prediction for 2031 points to an average of $5.40 (low $4.02, high $7.82) — a potential gain of +155% on today's $2.12. Momentum favours further upside here.
In 2032, PLX is projected to trade between $5.14 and $10.31, averaging $7.01 — a potential gain of +230% from today's $2.12. That is up +30% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Protalix BioTherapeutics, Inc.'s 2033 outlook centres on $8.04, within a $5.82 to $12.02 range. That is up +15% on the projected 2032 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2034, PLX could reach as high as $12.90, with a base case around $8.51 and support toward $6.08 — roughly +302% from $2.12. Buyers look set to stay in control over this stretch.
Expect PLX to range from $6.44 to $14.02 through 2035. The $9.13 average target implies a +330% move from current prices. That is up +7% on the projected 2034 average. Momentum favours further upside here.
The PLX price prediction for 2040 points to an average of $16.55 (low $11.04, high $26.87) — a potential gain of +681% on today's $2.12. Buyers look set to stay in control over this stretch.
In 2050, PLX is projected to trade between $21.83 and $63.40, averaging $35.98 — a potential gain of +16.0x from today's $2.12. That is up +117% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PLX today (≈ 471.698113 PLX) could be worth
$16,972.79
+$15,972.79 (+1597%) by 2050 · US Dollar
Based on the average projected PLX price of $35.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PLXwould be worth at today's price.
$1,000 invested in PLX on May 27, 2025 (≈ 641.025665 PLX) would be worth
$1,358.97
+$358.97 (+35.9%) today · 1.36× · US Dollar
Based on a PLX entry price of $1.56 vs. today's $2.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.01 | $1,054.73 | +5.5% |
| 1 month ago | $2.16 | $981.48 | -1.9% |
| 3 months ago | $3.01 | $704.32 | -29.6% |
| 6 months ago | $1.78 | $1,191.01 | +19.1% |
| 1 year ago | $1.56 | $1,358.97 | +35.9% |
| All time (5.0y) ago | $2.98 | $711.41 | -28.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PLX forecast.
Our base-case forecast reaches $4.20 around 2030.
Implied market cap at $4.20: $338.4M
The multi-year forecast shows a clear uptrend in average price starting in 2026 at $2.10 and moving higher in subsequent years. By 2027 the avg is $3.15 with a bullish sentiment and a 50% ROI; in 2028 the avg is $3.64 and the ROI is 73.3%; in 2029 the avg is $4.03 with a 92.1% ROI; in 2030 the avg is $4.66 with a 121.8% ROI and a bullish sentiment. By 2040 the avg price is $17.20 with a min of $11.30 and a max of $28.32, and the ROI is 719% with a bullish sentiment.
By 2050 the avg price is $37.72 with a min of $22.40 and a max of $67.57, and the ROI is 1696.3% with a bullish sentiment. These are estimates, not guarantees, and carry uncertainty about future performance.
Tap a question to reveal the answer.
2030 avg $4.66, min $3.50, max $6.68, ROI 121.8%, sentiment BULLISH.
Forecasts show bullish sentiment in 2030 and beyond, with rising averages (e.g., 2030 avg $4.66 and 2050 avg $37.72) and ROIs up to 1696.3%.
Yes—the max forecast in 2050 is $67.57, which would exceed $50.
Current price is $2.10 and market cap is $169.2M.
The 30-day range is $1.78 to $2.48.
Protalix BioTherapeutics, Inc. Community Discussion
0Share your Protalix BioTherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.